Your browser doesn't support javascript.
loading
Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine.
Conway, James Rw; Herrmann, David; Evans, Tr Jeffry; Morton, Jennifer P; Timpson, Paul.
Affiliation
  • Conway JR; Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Cancer Division, Sydney, New South Wales, Australia.
  • Herrmann D; Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Cancer Division, Sydney, New South Wales, Australia.
  • Evans TJ; St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
  • Morton JP; Cancer Department, Cancer Research UK Beatson Institute, Glasgow, UK.
  • Timpson P; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
Gut ; 68(4): 742-758, 2019 04.
Article in En | MEDLINE | ID: mdl-30396902
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Pancreatic Neoplasms / Carcinoma, Pancreatic Ductal / Protein Kinase Inhibitors / Precision Medicine / Phosphoinositide-3 Kinase Inhibitors Limits: Humans Language: En Year: 2019 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Pancreatic Neoplasms / Carcinoma, Pancreatic Ductal / Protein Kinase Inhibitors / Precision Medicine / Phosphoinositide-3 Kinase Inhibitors Limits: Humans Language: En Year: 2019 Type: Article